Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics (CMMB) reported its Q2 2022 financial results, highlighting significant progress in its clinical programs, particularly CM-101, a monoclonal antibody targeting fibrosis and inflammation. The company concluded the treatment phase of a Phase 2 trial for liver fibrosis in NASH patients, with topline results expected by year-end. Chemomab also received a U.S. patent for CM-101 in liver diseases, extending its protection until at least 2038. Financially, the company had $51.8 million in cash, with a net loss of $6.2 million for the quarter.
Chemomab Therapeutics (Nasdaq: CMMB) announced the appointment of Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. These appointments aim to strengthen the development of CM-101, a monoclonal antibody targeting fibrotic and inflammatory diseases. Key upcoming events include reporting topline results from a Phase 2 trial in liver fibrosis and launching a Phase 2 trial for systemic sclerosis. Both executives bring significant expertise that is expected to accelerate Chemomab's clinical activities and pipeline programs.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced it will release its second quarter 2022 financial results and provide a business update on August 12, 2022, at 8:00 am Eastern Time. During this event, the management team will review Q2 performance, discuss recent developments, and host a live Q&A session. The company specializes in developing therapeutics for fibrotic and inflammatory diseases, focusing on its monoclonal antibody CM-101, which is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported significant findings from presentations at the 2022 EASL International Liver Congress and the First International Extracellular Matrix Pharmacology Congress. The data highlights the role of the soluble protein CCL24 in liver diseases, specifically primary sclerosing cholangitis (PSC). Findings suggest that Chemomab's CCL24 neutralizing antibody CM-101 can effectively influence extracellular matrix remodeling, showing promise in clinical applications for PSC. The studies support the ongoing development of CM-101 in Phase 2 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has appointed Jill M. Quigley to its board of directors. Quigley brings over 20 years of experience in biotechnology leadership, including executive roles in management, operations, and legal affairs. Her expertise includes working with companies focused on innovative therapeutics for rare diseases. Chemomab is advancing its antibody CM-101 through clinical trials for serious conditions like primary sclerosing cholangitis and systemic sclerosis. This appointment is expected to enhance Chemomab's strategic direction and operational efficacy.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its participation in various investor and scientific conferences in June 2022, aimed at presenting its groundbreaking work in fibrotic and inflammatory diseases. Notable events include the JMP Securities Life Sciences Conference on June 16 in New York, and the Extracellular Matrix Pharmacology Congress from June 23-25 in Copenhagen. Chemomab's lead asset, CM-101, is in Phase 2 trials for several severe conditions, including primary sclerosing cholangitis, and is expected to advance into systemic sclerosis trials later this year.
Chemomab Therapeutics reported significant findings regarding CCL24 as a therapeutic target for systemic sclerosis at the EULAR European Congress of Rheumatology. Their CCL24-neutralizing antibody, CM-101, is set to enter Phase 2 trials later this year. The study indicated elevated CCL24 levels correlated with disease activity and prognosis in diffuse cutaneous systemic sclerosis patients. These findings strengthen the rationale for CM-101's clinical trials, aimed at addressing a critical unmet need in treating this severe autoimmune disease.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual H.C. Wainwright Global Investment Conference from May 23-26, 2022. Management will deliver a corporate overview webcast available on demand starting at 7:00 am ET on May 24. Additionally, Chemomab will engage in one-on-one meetings with investors. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in Phase 2 trials for severe conditions like primary sclerosing cholangitis and lung fibrosis.
Chemomab Therapeutics (CMMB) reported its Q1 2022 financial results, revealing a net loss of $5.1 million, or $0.02 per share, compared to a $1.7 million loss in Q1 2021. Cash and equivalents decreased to $57.5 million from $61.2 million at year-end 2021. R&D expenses rose significantly to $2.7 million, while G&A expenses jumped to $2.6 million, influenced by stock-based compensation. The company is progressing in its CM-101 clinical trial for fibrotic diseases, expanding into new regions, with an interim analysis expected later this year.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its first quarter 2022 financial results and provide a business update on May 12, 2022, during a conference call at 8:00 am ET. The call will review performance, recent events, and feature a live Q&A session. Chemomab focuses on developing therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in two Phase 2 trials for severe conditions affecting the liver and systemic sclerosis. For further details, visit chemomab.com.
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
